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Abstract
Background: Arteriovenous ﬁstula (AVF) failure to mature (FTM) rates contribute to excessive dependence on central venous
catheters for haemodialysis. Choosing the most appropriate vascular access site for an individual patient is guided largely by
their age, co-morbidities and clinical examination. We investigated the clinical predictors of AVF FTM in a European cohort of
patients and applied an existing clinical risk prediction model for AVF FTM to this population.
Methods: A prospective cohort study was designed that included all patients undergoing AVF creation between January 2009
and December 2014 in a single centre (Belfast City Hospital) who had a functional AVF outcome observed by March 2015.
Results: A total of 525 patients had a functional AVF outcome recorded and were included in the FTM analysis. In this cohort,
309 (59%) patients achieved functional AVF patency and 216 (41%) patients had FTM. Female gender [P < 0.001, odds ratio (OR)
2.03 (CI 1.37–3.02)] and lower-arm AVF [P < 0.001, OR 4.07 (CI 2.77–5.92)] were associated with AVF FTM. The Lok model did not
predict FTM outcomes based on the associated risk stratiﬁcation in our population.
Conclusions: In this European study, female gender was associated with twice the risk of AVF FTM and a lower-arm AVF with
four times the risk of FTM. The FTM risk prediction model was not found to be discriminative in this population. Clinical risk
factors for AVF FTM vary between populations; wewould recommend that units investigate their own clinical predictors of FTM
to maximize AVF functional patency and ultimately survival in dialysis patients. Clinical predictors of AVF FTM may not be
sufﬁcient on their own to improve vascular access functional patency rates.
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Introduction
United Kingdom renal registry data report that the relative risk of
death in individuals on renal replacement therapy ages 30–34
years is 18 times that of the general population, and in patients
>85 years it is 2.5 times that of the general population [1]. The
use of arteriovenous ﬁstulas (AVFs) compared with central
venous catheters (CVCs) for vascular access has been associated
with increased haemodialysis patient survival [2–4]. Initial use of
AVFs for haemodialysis varies widely, with an incident AVF use
rate of 14% in the USA compared with 32% in Europe [5, 6]. It is
well recognized that high rates of failure to mature (FTM) limit
widespread adoption of AVFs for vascular access [7].
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Although improved AVF outcomes have been associated with
strategies such as routine preoperative ultrasound mapping [8],
which identiﬁes optimal blood vessels prior to AVF creation,
these services are not always readily available [9] or indeed may
not inﬂuence surgical decision-making [10]. Thus, in the ‘real-
world’ setting, the renal teamoften relies on clinical characteristics,
such as the patient’s age and burden of co-morbidities, whichmay
inﬂuence vascular anatomy and survival, when deciding on the
best vascular access strategy for an individual patient.
A survey of Canadian and American nephrologists found that
patients were more likely to be referred for AVF creation if they
were <65 years old and hadminimal co-morbidities or no history
of failed vascular access attempts [11]. These ﬁndings were
echoed in an international survey of 134 surgeons examining
preference and practice in haemodialysis vascular access cre-
ation; increased co-morbidities and previous failed vascular
access procedures were seen as potential deterrents to AVF cre-
ation [10]. Of interest, 42% of surgeons stated that they had no
absolute contraindications to AVF creation.
Several studies in differing populations have identiﬁed a var-
iety of clinical factors associated with AVF FTM, such as age ≥65
years [12], female gender [13], uraemia [14], diabetes, peripheral
vascular disease (PVD) and non-white race [15]. In a recent
study of 17 000 Canadian patients, female gender and a higher
number of co-morbidities were associated with lower rates of
AVF creation [16]. The majority of studies reporting rates of AVF
FTM have been conducted in the USA, which has a distinctly dif-
ferent healthcare system, higher rates of co-morbidities such as
diabetes [17] and different ethnicity compared with European
countries.
In 2006, Lok et al. [12] published a scoring system for stratifying
AVF FTM risk based on clinical factors, designed to be used as an
adjunct in planning vascular access for haemodialysis. The scor-
ing system uses four clinical factors: age ≥65 years, race (white
race associated with the lowest risk of FTM), presence of cardio-
vascular disease andpresence of PVD to stratify patients into low,
moderate, high and very high risks of FTM. The authors subse-
quently validated this risk model in a combined American–
Canadian cohort of just over 400 patients. Our aim was to assess
the application of this scoring system in a European population.
Materials and methods
Study setting and population
A prospective cohort study was designed that incorporated all
patients undergoing native AVF creation between January 2009
and December 2014 in a single centre (Belfast City Hospital)
who had a functional AVF outcome by March 2015. Functional
outcomes were deﬁned as follows:
Primary patency: Two-needle use of the AVF on haemodialy-
sis for at least six consecutive sessions without further
intervention following creation.
Primary assisted patency: AVF that required surgical or radio-
logical intervention after initial creation before being used
with two needles on haemodialysis for at least six consecu-
tive sessions.
Functional patency: All AVFs used for two-needle dialysis.
Functional patency was a combination of primary and
primary assisted patency.
Failure to mature: Deﬁned either by clinical examination
or failure to sustain two-needle dialysis for at least six
consecutive dialysis sessions.
Logistic regression was used to explore predictors of AVF FTM in
the Belfast cohort. The Lok AVF FTM risk model [12] was then
subsequently applied to our cohort. This risk model allows the
formulation of a risk score to categorize FTM risk.
The risk score is calculated on the basis of the following:
- Age ≥65 years = 2 points
- Presence of coronary artery disease (CAD) (deﬁned as cor-
onary stenosis detected by angiography, history of myocar-
dial infarction, previous coronary revascularization by
angioplasty, stenting or cardiac bypass surgery) = 2.5 points
- Presence of PVD (deﬁned as lower extremity revasculariza-
tion, digit or extremity amputation, history of claudication
and ischaemic extremity changes or gangrene) = 3 points
- White race =minus 3 points.
All patients receive a baseline score of 3 points.
The resultant overall score stratiﬁes the patients into low risk
(<2.0),moderate risk (2.0–3.0), high risk (3.1–6.9) and very high risk
(7.0).
The Lok et al. derivation cohort [12] was comprised of 422 pa-
tients in Toronto (ON, Canada) who had received a ﬁrst AVF be-
tween 1 January 1995 and 1 January 2004.
Data collection and study population
The Northern Ireland Vascular Access Database for Chronic
Kidney Disease (ethics approval reference number 14/NI/1105)
incorporates clinical and vascular access data on patients with
advanced chronic kidney disease. Recorded patient characteris-
tics included gender, age, race, primary renal disease, type of vas-
cular access, anticoagulation use and co-morbidities including
diabetes, CAD and PVD. The database was interrogated for
these clinical characteristics in patients who had a functional
AVF outcome by 1 March 2015. The ethics committee waived
the need for individual patient consent. Each patient was only in-
cluded once using outcome data on the ﬁrst AVF created during
January 2009–December 2014.
With regard to our vascular access creation strategy, our pre-
vious practice was to start distally in the non-dominant arm and
then proceed proximally; i.e. a radiocephalic (wrist or proximal)
AVF is attempted ﬁrst, followed by a brachiocephalic AVF and
then lastly a brachiobasilic AVF, subsequently moving to the
dominant arm in order to preserve future vascular access op-
tions. Snuff-box AVFs and AVFs involving either the ulnar artery
or forearm basilic vein were not created as standard practice in
our centre. Since 2011, there has been increasing application of
ultrasound assessment to help guide the choice of AVF creation
site with minimum vessel diameters of 2 mm.
Following anastamosis, appropriate venous dilation must
occur if an AVF is to mature successfully. During manipulation
of the vein, it may spasm. Our surgical practice is to minimize
handling of the blood vessel and to ﬂush the outﬂow vein with
a heparinized saline solution. Vasodilating agents are not used
in our centre. Regarding the cannulation of new AVFs, it is our
practice to carry out single-needle double-pump dialysis for the
ﬁrst three dialysis sessions and then subsequently establish all
of our patients on two-needle dialysis.
Statistical analysis
The following clinical variables were identiﬁed for investigation
regarding AVF FTM outcome prior to data collection: age, gender,
renal replacement therapy status at AVF creation, diabetic status,
CAD, PVD, anticoagulation use, previous AVF and location of AVF
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creation (upper-arm versus lower-arm site). Statistical analysis
was performed using SPSS version 22 (IBM, Armonk, NY, USA).
Logistic regression was used to identify variables in the
Belfast cohort that contributed signiﬁcantly to predicting AVF
FTM, as it disentangles the effects of correlated explanatory
variables and takes account of confounders. The backward elim-
ination approach was subsequently used to select the best set of
independent variables.
The χ² test was used to compare baseline clinical characteris-
tics between the Belfast cohort and the Lok model derivative
cohort. As stated above, the Lok et al. prediction score [12] strati-
ﬁes patients into low risk (<2.0), moderate risk (2.0–3.0), high risk
(3.1–6.9) and very high risk (7.0) of AVF FTM. This score was sub-
sequently used to stratify the Belfast cohort into the associated
categories. Logistic regression analysis was subsequently used
to assess for a signiﬁcant difference between the low-risk cat-
egory (set as a baseline categorical variable) FTM outcome and
the other risk categories.
Results
A total of 688 patients were identiﬁed who had an AVF created by
one of ﬁve consultant surgeons during this 6-year period. A func-
tional AVF outcome was available for 538 patients on 1 March
2015. Of these, ﬁve patients had early technical failure and
eight patients had their AVF ligated due to vascular steal before
use. These 13 patients were excluded from the FTM analysis,
leaving 525 patients that had a functional AVF outcome by 1
March 2015.
A total of 309 (59%) patients achieved functional AVF patency
(primary patency n = 261, primary assisted patency n = 48), while
216 patients (41%) had FTM. In this cohort, 78% (240/309) of pa-
tients achieved functional patency after the creation of a single
AVF.
Of the 216 patientswho hadAVF FTM, 44% (95/216) hadno fur-
ther surgical vascular access attempts and 56% (121/216) went on
to have a mean of two further attempts at AVF creation. A func-
tionally patent AVF was achieved in 71% (86/121) of patients who
had further attempted AVF creation after initial FTM. In our clin-
ical practice, the decision to reattempt further AVF creation is in-
ﬂuenced by age, co-morbidities, remaining vessel ultrasound
mapping characteristics and the option of an alternative renal re-
placement modality such as the availability of a living kidney
donor.
With regard to exploring the predictors of AVF FTM, results of
logistic regression analysis of multiple clinical variables are
shown in Table 1.
Backward elimination revealed that female gender [P < 0.001,
odds ratio (OR) 2.04 (CI 1.37–3.02)] and lower-arm AVF [P < 0.001,
OR 4.07 (CI 2.77–5.92)] were associated with AVF FTM in the
Belfast cohort. Age, including age >80 years, was not associated
with increased risk of FTM [P = 0.63, OR 1.12 (CI 0.69–1.83)].
Following these ﬁndings, subgroup analysis of the 186 female
patients was subsequently carried out for the purposes of hy-
pothesis generation. In the female cohort, only a lower-arm
AVF was associated with a 4-fold risk of FTM [P < 0.001, OR 3.86
(CI 2.08–7.14)].
The Lok et al. AVF FTM risk prediction model [12] was then
applied to the Belfast cohort. The clinical characteristics of the
Belfast AVF cohort in comparisonwith the Lok et al. derivation co-
hort are shown in Table 2. In contrast to the Toronto cohort, the
Belfast AVF cohort had higher proportions of older, white and
diabetic patients.
Following stratiﬁcation of the Belfast cohort into the risk
categories of the Lok et al. AVF FTM predictionmode [12], the pro-
portion of patients with AVF FTM was 41% in the low-risk group,
45% in the moderate-risk group and 44% in the high- and very-
high-risk groups (the predicted FTM rates for each of these
categories based on the model were 25, 35, 50 and 70%, respect-
ively). These differences in rates of FTM are illustrated in Figure 1.
Using the Lok et al. risk as a categorical variable with the low-
risk group representing the baseline, logistic regression analysis
for predictors of AVF FTM showed no difference between FTM
outcomes in the moderate- [P = 0.28, OR 0.62 (CI 0.26–1.49)],
high- [P = 0.52, OR 0.75 (CI 0.31–1.81)] and very-high-risk categor-
ies [P = 0.45, OR 0.72 (CI 0.29–1.9)] comparedwith the low-risk cat-
egory. Using receiver operator characteristic (ROC) analysis to
investigate the ability of the model to predict FTM in this cohort
revealed an area under the curve (C statistic) of 0.53 (P = 0.23, CI
0.48–0.58) (Figure 2). Thus, in our cohort of AVF patients, the
Lok et al. risk model [12] did not discriminate between FTM
outcomes.
Discussion
The lowest mortality rates in haemodialysis patients have been
associated with AVF use and the highest mortality associated
with CVC use for vascular access [3]. High rates of FTM are a
major limiting factor to achieving optimal rates of incident and
prevalent AVF use. The ability to stratify patients into AVF FTM
risk categories is important in order to maximize patient out-
comes and efﬁciently utilize limited healthcare resources. Our
AVF patency rate is similar to other studies [13, 18].
Multiple studies have investigated clinical predictors of FTM
with no general consensus [15, 19–21]. In our population of 525
patients, female gender and lower-arm AVF site were the only
predictors of AVF FTM.
Female gender has been associated with increased risk of AVF
FTM in several studies [15, 16, 22–24]. The reason for this remains
unclear. In our cohort, there was no correlation between
Table 1. Logistic regression analysis of predictors of AVF FTM in the Belfast cohort
Clinical characteristic (reference category) Odds ratio 95% CI P-value
Female gender (male = 0, female = 1) 2.14 1.43–3.19 <0.001
Age ≥65 years (age < 65 years = 0, age ≥65 = 1) 0.95 0.65–1.40 0.81
Lower-arm site (lower-arm AVF = 1, upper arm = 0) 4.24 2.86–6.27 <0.001
CKD at AVF creation (CKD = 1, HD = 2) 1.20 0.85–1.67 0.31
Anticoagulation (yes = 1, no = 0) 1.02 0.68–1.56 0.92
Co-morbidities
Diabetes mellitus (yes = 1, no = 0) 0.93 0.62–1.40 0.74
PVD (yes = 1, no = 0) 1.55 0.84–2.86 0.16
Ischaemic heart disease (yes = 1, no = 0) 1.32 0.84–2.06 0.23
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co-morbidities and increased risk of FTM in the female subgroup.
Historically, the higher risk of FTM in females was attributed to
smaller blood vessel diameter compared with males. However,
despite female blood vessels being smaller in calibre than the
equivalents in males, arterial diameters in females have been
shown to be larger than the recommended minimum diameter
of 2.0 mm [25] with similar venous diameters [26–28].
Following AVF creation, the feeding artery is required to ac-
commodate a signiﬁcantly increased blood ﬂow; thus, arterial
distensibility is likely to play a vital role in AVFmaturation poten-
tial [29]. In a study of preoperative ultrasound assessment of ra-
dial artery characteristics prior to AVF creation, Lockhart et al. [26]
found that female patients undergoing dialysis had amarked in-
ability to increase their preoperative peak systolic ﬂow following
a clenched ﬁst manoeuvre. This feature was associated with AVF
FTM. A prospective European study of 122 patients by Jemkov [30]
suggested that female patients require a longer period to attain
AVF maturation despite having better endothelial function than
men and recommended earlier AVF creation in this cohort of
patients.
As found in our study, lower-armAVFs arewell known to have
higher rates of FTM compared with upper-arm AVFs [23, 31]. The
ﬁndings of higher AVF FTM in female patients and in lower-arm
AVFs suggest that these patients may beneﬁt from additional
routine preoperative workup such as ultrasound mapping to
identify the best blood vessels prior to attempted vascular access
creation.
Age has been associated with increased AVF FTM in several
studies [12, 15, 32]. Northern Ireland has one of the oldest cohorts
of dialysis patients in the UK; in 2013, the median age of incident
dialysis patients was 67 years [33], so Belfast is well placed to ex-
plore the role of age in AVFoutcomes. It is interesting that even in
patients >80 years, age was not associated with AVF FTM in our
cohort, an observation that has been noted in other populations
[34, 35].
The Lok et al. risk prediction model [12] for FTM is the only ex-
isting model for predicting AVF FTM based on purely clinical fac-
tors. Like us, Lilly et al. [15] found thismodel to be of limited value
in predicting incident AVF use in an American cohort of haemo-
dialysis patients. One of the reasons themodel is not predictive in
the Belfast cohortmay be the differences in race composition; the
Toronto cohort was 65.8%white and the Belfast cohort was 98.5%
white. The predominantly white racial composition of the Belfast
cohort is similar to the majority of European populations, which
could suggest that the Lok et al. [12]modelmay be of limited value
for European populations. This requires further investigation.
Table 2. Comparison of clinical characteristics in the Lok et al. [12] derivation model AVF cohort and Belfast AVF cohort
Clinical characteristics Original Lok cohort (n = 422) Belfast cohort (n = 525) P-value
Mean age, SD (range) 58 years, 17.5 (17–90) 64 years, 15 (14–93) <0.001
Age ≥65 years 184 (44%) 288 (55%) <0.001
Female gender 136 (32%) 186 (35%) 0.301
Race, white 278 (65.8%) 517 (98. 5%) <0.001
Cause of ESRD
Diabetes 104 (24.6%) 137 (26.1%) 0.653
Hypertension 102 (24.2%) 41 (7.8%) <0.001
Glomerulonephritis 111 (26.3%) 85 (16.2%) <0.001
Co-morbidities
Diabetes mellitus 120 (28%) 193 (37%) 0.007
CAD 136 (32%) 155 (30%) 0.370
PVD 35 (8%) 57 (11%) 0.186
Anticoagulation use 260 (50%) Not reported
Pre-dialysis at creation 194 (46%) 277 (53%) 0.038
AVF type
Lower arm 256 (60.7%) 267 (51%) 0.001
Fig. 1. Observed clinical FTM outcomes in the Belfast AVF cohort versus the
predicted outcomes for this cohort using the Lok et al. risk model [12].
Fig. 2. Receiver operating analysis curve of the Lok et al. model [12] as a predictor of
AVF FTM (area under the curve 0.53, P = 0.27, standard error 0.03, 95%CI 0.49–0.58).
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In both the US and Belfast populations, it is difﬁcult to disen-
tangle the effects of variables such as preoperative ultrasound
mapping assessment and nephrological and surgical preferences
in clinical practice [15]. Increasingly in our centre, ultrasound
mapping is used to identify the best blood vessels and vascular
access creation is then tailored to the individual. Routine ultra-
soundmapping at a nephrologist-led (J.B.H.) vascular access clin-
ic was introduced in August 2011. For the elderly (age ≥65 years)
or patients deemed to need dialysis initiation in a short period of
time,we try to use the ‘best option’ identiﬁed by ultrasoundmap-
ping (lower or upper arm) to create the optimum AVF. During
January 2009–December 2014, ﬁve surgeons have created AVFs
at the Belfast City Hospital. One surgeon preferred a distal AVF
ﬁrst followed by a proximal AVF approach, two surgeons
performed ultrasound measurements themselves, while the re-
maining two surgeons createdAVFs on the basis of recommenda-
tions from the vascular access clinic ﬁndings (149/525 patients
in this study). These differences and changes in practice are
not readily accounted for in analyses, but are likely to have
inﬂuenced AVF outcomes.
However, our results do show that positive AVF outcomes can
be obtained in patients determined to be at high risk of AVF FTM
based on age and co-morbidities; we would recommend that
these variables alone should not be used to exclude patients
from AVF creation.
Factors associated with AVF FTM are likely to vary from popu-
lation to population. It is important to investigate local rates of
AVF FTM and associated predictors of AVF patency in order to
guide appropriate vascular access decision-making. For example,
is the minimum preoperative vein diameter or radial artery vol-
ume ﬂow in a 75-year-old female patient with diabetes the
same as a 75-year-old female without diabetes? Information
obtained from further studies should facilitate the creation of
regionally applicable predictive models encompassing a com-
bination of clinical and ultrasound parameters to help stratify
patients into relevant categories of risk for AVF FTM.
Region-speciﬁc studies are required to guide appropriate
vascular access management, thereby avoiding futile procedures
and optimizing AVF access rates with the goal of enhancing
survival in our dialysis patients.
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